Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model

被引:118
作者
Naqvi, Kiran [1 ]
Garcia-Manero, Guillermo [1 ]
Sardesai, Sagar [1 ]
Oh, Jeong [1 ]
Vigil, Carlos E. [1 ]
Pierce, Sherry [1 ]
Lei, Xiudong [1 ]
Shan, Jianqin [1 ]
Kantarjian, Hagop M. [1 ]
Suarez-Almazor, Maria E. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
SCORING SYSTEM; CO-MORBIDITY; EVALUATING PROGNOSIS; LIFE EXPECTANCY; CANCER-PATIENTS; RISK; CLASSIFICATION; DISEASE; IMPACT; AGE;
D O I
10.1200/JCO.2010.31.3353
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Patients with cancer often experience comorbidities that may affect their prognosis and outcome. The objective of this study was to determine the effect of comorbidities on the survival of patients with myelodysplastic syndrome (MDS). Patients and Methods We conducted a retrospective cohort study of 600 consecutive patients with MDS who presented to MD Anderson Cancer Center from January 2002 to December 2004. The Adult Comorbidity Evaluation-27 (ACE-27) scale was used to assess comorbidities. Data on demographics, International Prognostic Scoring System (IPSS), treatment, and outcome (leukemic transformation and survival) were collected. Kaplan-Meier methods and Cox regression were used to assess survival. A prognostic model incorporating baseline comorbidities with age and IPSS was developed to predict survival. Results Overall median survival was 18.6 months. According to the ACE-27 categories, median survival was 31.8, 16.8, 15.2, and 9.7 months for those with none, mild, moderate, and severe comorbidities, respectively (P < .001). Adjusted hazard ratios were 1.3, 1.6, and 2.3 for mild, moderate, and severe comorbidities, respectively, compared with no comorbidities (P < .001). A final pognostic model including age, IPSS, and comorbidity score predicted median survival of 43.0, 23.0, and 9.0 months for lower-, intermediate-, and high-risk groups, respectively (P < .001). Conclusion Comorbidities have a significant impact on the survival of patients with MDS. Patients with severe comorbidity had a 50% decrease in survival, independent of age and IPSS risk group. A comprehensive assessment of the severity of comorbidities helps predict survival in patients with MDS. J Clin Oncol 29: 2240-2246. (C) 2011 by American Society of Clinical Oncology
引用
收藏
页码:2240 / 2246
页数:7
相关论文
共 29 条
[1]   The impact of co-morbidity on life expectancy among men with localized prostate cancer [J].
Albertsen, PC ;
Fryback, DG ;
Storer, BE ;
Kolon, TF ;
Fine, J .
JOURNAL OF UROLOGY, 1996, 156 (01) :127-132
[2]  
BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x
[3]   A NEW CLINICAL ANATOMIC STAGING SYSTEM FOR EVALUATING PROGNOSIS AND TREATMENT OF PROSTATIC-CANCER [J].
CLEMENS, JD ;
FEINSTEIN, AR ;
HOLABIRD, N ;
CARTWRIGHT, S .
JOURNAL OF CHRONIC DISEASES, 1986, 39 (11) :913-928
[4]   Cause of Death in Patients With Lower-Risk Myelodysplastic Syndrome [J].
Dayyani, Farshid ;
Conley, Anthony P. ;
Strom, Sara S. ;
Stevenson, William ;
Cortes, Jorge E. ;
Borthakur, Gautam ;
Fader, Stefan ;
O'Brien, Susan ;
Pierce, Sherry ;
Kantarjian, Hagop ;
Garcia-Manero, Guillermo .
CANCER, 2010, 116 (09) :2174-2179
[5]   Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome [J].
Della Porta, Matteo Giovanni ;
Malcovati, Luca .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (05) :602-606
[6]   Prognostic value of clinical variables in ovarian cancer [J].
DiSilvestro, P ;
Peipert, JF ;
Hogan, JW ;
Granai, CO .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (05) :501-505
[7]   Measurement and impact of comorbidity in older cancer patients [J].
Extermann, M .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 35 (03) :181-200
[8]   PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE [J].
FEINSTEIN, AR .
JOURNAL OF CHRONIC DISEASES, 1970, 23 (07) :455-+
[9]   A prognostic score for patients with lower risk myelodysplastic syndrome [J].
Garcia-Manero, G. ;
Shan, J. ;
Faderl, S. ;
Cortes, J. ;
Ravandi, F. ;
Borthakur, G. ;
Wierda, W. G. ;
Pierce, S. ;
Estey, E. ;
Liu, J. ;
Huang, X. ;
Kantarjian, H. .
LEUKEMIA, 2008, 22 (03) :538-543
[10]   International scoring system for evaluating prognosis in myelodysplastic syndromes [J].
Greenberg, P ;
Cox, C ;
LeBeau, MM ;
Fenaux, P ;
Morel, P ;
Sanz, G ;
Sanz, M ;
Vallespi, T ;
Hamblin, T ;
Oscier, D ;
Ohyashiki, K ;
Toyama, K ;
Aul, C ;
Mufti, G ;
Bennett, J .
BLOOD, 1997, 89 (06) :2079-2088